Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold
S Ahlgren, A Orlova, H Wållberg… - Journal of nuclear …, 2010 - Soc Nuclear Med
Overexpression of the human epidermal growth factor receptor type 2 (HER2) in breast
carcinomas predicts response to trastuzumab therapy. Affibody molecules based on a …
carcinomas predicts response to trastuzumab therapy. Affibody molecules based on a …
Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
H Honarvar, C Müller, S Cohrs, S Haller… - Nuclear medicine and …, 2017 - Elsevier
Introduction Affibody molecules are small (58 amino acids) high-affinity proteins based on a
tri-helix non-immunoglobulin scaffold. A clinical study has demonstrated that PET imaging …
tri-helix non-immunoglobulin scaffold. A clinical study has demonstrated that PET imaging …
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
AC Steffen, A Orlova, M Wikman, FY Nilsson… - European journal of …, 2006 - Springer
Purpose Targeted delivery of radionuclides for diagnostic and therapeutic applications has
until recently largely been limited to receptor ligands, antibodies and antibody-derived …
until recently largely been limited to receptor ligands, antibodies and antibody-derived …
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
AC Steffen, Y Almqvist, MK Chyan… - Oncology …, 2007 - spandidos-publications.com
The size of affibody molecules makes them suitable as targeting agents for targeted
radiotherapy with the α-emitter 211At, since their biokinetic properties match the short …
radiotherapy with the α-emitter 211At, since their biokinetic properties match the short …
[HTML][HTML] Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
Radionuclide molecular imaging of human epidermal growth factor receptor 3 (HER3)
expression using affibody molecules could be used for patient stratification for HER3 …
expression using affibody molecules could be used for patient stratification for HER3 …
Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting Affibody molecule–albumin-binding domain fusion protein
A Orlova, A Jonsson, D Rosik, H Lundqvist… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Because of their better penetration, smaller targeting proteins may be superior to antibodies
for radioimmunotherapy of solid tumors. Therefore, Affibody molecules (6.5 kDa) have a …
for radioimmunotherapy of solid tumors. Therefore, Affibody molecules (6.5 kDa) have a …
The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy
V Tolmachev, H Wållberg, K Andersson… - European journal of …, 2009 - Springer
Purpose Affibody molecules represent a novel class of high-affinity agents for radionuclide
tumour targeting. Fusion of the Affibody molecules with an albumin-binding domain (ABD) …
tumour targeting. Fusion of the Affibody molecules with an albumin-binding domain (ABD) …
Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition
V Tolmachev, TA Tran, D Rosik, A Sjöberg… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Radionuclide imaging of cancer-associated molecular alterations may contribute to patient
stratification for targeting therapy. Scaffold high-affinity proteins, such as Affibody molecules …
stratification for targeting therapy. Scaffold high-affinity proteins, such as Affibody molecules …
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
J Sörensen, D Sandberg, M Sandström… - Journal of nuclear …, 2014 - Soc Nuclear Med
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts the
response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered …
response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered …
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine
S Ahlgren, H Wållberg, TA Tran… - Journal of Nuclear …, 2009 - Soc Nuclear Med
The detection of human epidermal growth factor receptor type 2 (HER2) expression in
malignant tumors provides important information influencing patient management …
malignant tumors provides important information influencing patient management …
Related searches
- molecular imaging affibody molecule
- her2 expression affibody molecule
- bz dota affibody molecules
- domain fusion affibody molecule
- radiometal labeling affibody molecule
- engineered cysteine affibody molecule
- chx a dtpa affibody molecules
- influence of chelator affibody molecules
- site composition affibody molecules
- preclinical assessment affibody molecule
- interplay of affinity affibody molecules
- her2 expression molecular imaging